Literature DB >> 15645429

Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1.

Joseph T Chang1, Hung-Ming Wang, Ku-Wei Chang, Wen-Ho Chen, Ming-Chun Wen, Yuan-Ming Hsu, Benjamin Yat-Ming Yung, I-How Chen, Chun-Ta Liao, Ling-Ling Hsieh, Ann-Joy Cheng.   

Abstract

To identify cellular genes that could potentially serve as predictive molecular markers for human oral cancer, we employed differential display analysis to compare the gene expression profiles between oral squamous cell carcinoma (OSCC) and histopathologically normal epithelium tissues. Comparative real-time RT-PCR was used to confirm the gene expression in 52 OSCC patients, and a 2-fold difference was defined as over- or underexpression. A total of 7 genes were identified: NPM, CDK1, NDRG1, HMGCR, EF1A, NAC and CHES1. In the cancer tissues, NPM, CDK1 and NDRG1 were significantly overexpressed (an average of 7.6-, 17.2- and 12.9-fold, respectively), and CHES1 was underexpressed (15-fold). The frequencies of the differential expression were 40, 56, 67 and 46%, respectively in NPM, CDK1, NDRG1 and CHES1. In Western blot analysis, the protein expressions of NPM, CDK1 and NDRG1 were also increased in the cancer tissues, consistent with the mRNA expression results. To further evaluate clinicopathological associations in these genes, Pearson chi-square analysis was employed. Levels of CDK1 and NDRG1 were associated with poorly differentiated tumors (p = 0.043 and 0.023), suggesting that these genes participate in the mechanism of tumor transformation. Expressions of CDK1 and NDRG1, and CDK1 and CHES1 were mutually statistically correlated (p = 0.001 and 0.014), indicating that these genes share a very close regulatory relationship or interact synergistically in oncogenesis. In conclusion, we identified 7 genes that are differentially expressed in OSCC, and we provide the first evidence that NPM, CDK1 and NDRG1 are overexpressed and CHES1 is underexpressed in oral cancer. These results serve as a fundamental base for employing these genes in future clinical applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15645429     DOI: 10.1002/ijc.20663

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.

Authors:  Rolf K Swoboda; Rajasekharan Somasundaram; Laura Caputo; Klara Berencsi; Paul von Franzke; Douglas D Taylor; Francesco M Marincola; Neal J Meropol; Elin Sigurdson; Eric Miller; Dorothee Herlyn
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

2.  The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer.

Authors:  Wanjin Li; Zihan Zhang; Xinhua Liu; Xiao Cheng; Yi Zhang; Xiao Han; Yu Zhang; Shumeng Liu; Jianguo Yang; Bosen Xu; Lin He; Luyang Sun; Jing Liang; Yongfeng Shang
Journal:  J Clin Invest       Date:  2017-08-14       Impact factor: 14.808

3.  Over-expression of p53, p21 and Cdc2 in histologically negative surgical margins is correlated with local recurrence of laryngeal squamous cell carcinoma.

Authors:  Jun-Quan Yang; Hong-Xia Liu; Zhen Liang; Yu-Man Sun; Meng Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Laryngeal squamous cell carcinoma cell lines show high tolerance for siRNA-mediated CDK1 knockdown.

Authors:  Kinga Bednarek; Magdalena Kostrzewska-Poczekaj; Adam Ustaszewski; Joanna Janiszewska; Katarzyna Kiwerska; Julia Paczkowska; Reidar Grenman; Maciej Giefing; Malgorzata Jarmuz-Szymczak
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

5.  Models for Predicting Stage in Head and Neck Squamous Cell Carcinoma Using Proteomic and Transcriptomic Data.

Authors:  Chanchala D Kaddi; May D Wang
Journal:  IEEE J Biomed Health Inform       Date:  2015-10-08       Impact factor: 5.772

6.  Transcriptomic characterization of differential gene expression in oral squamous cell carcinoma: a meta-analysis of publicly available microarray data sets.

Authors:  Yang Sun; Zhijian Sang; Qian Jiang; Xiaojun Ding; Youcheng Yu
Journal:  Tumour Biol       Date:  2016-10-04

7.  Prognostic significance of NDRG1 expression in oral and oropharyngeal squamous cell carcinoma.

Authors:  Marcelo Dos Santos; Ana Maria da Cunha Mercante; Fábio Daumas Nunes; Andréia Machado Leopoldino; Marcos Brasilino de Carvalho; Diana Gazito; Rossana Verónica Mendoza López; Paula Blandina Olga Chiappini; Paulo Bentes de Carvalho Neto; Erica Erina Fukuyama; Eloiza Helena Tajara; Iúri Drumond Louro; Adriana Madeira Álvares da Silva
Journal:  Mol Biol Rep       Date:  2012-09-13       Impact factor: 2.316

8.  Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.

Authors:  Lang-Ming Chi; Chien-Wei Lee; Kai-Ping Chang; Sheng-Po Hao; Hang-Mao Lee; Ying Liang; Chuen Hsueh; Chia-Jung Yu; I-Neng Lee; Yin-Ju Chang; Shih-Ying Lee; Yuan-Ming Yeh; Yu-Sun Chang; Kun-Yi Chien; Jau-Song Yu
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

9.  Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma.

Authors:  Jarosław Markowski; Tomasz Tyszkiewicz; Michał Jarzab; Małgorzata Oczko-Wojciechowska; Tatiana Gierek; Małgorzata Witkowska; Jarosław Paluch; Małgorzata Kowalska; Zbigniew Wygoda; Dariusz Lange; Barbara Jarzab
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-07-16       Impact factor: 2.503

10.  Loss of heterozygosity at chromosome 14q is associated with poor prognosis in head and neck squamous cell carcinomas.

Authors:  Davut Pehlivan; Esra Gunduz; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Bekir Beder; Beyhan Cengiz; Rosario S Rivera; Kunihiro Fukushima; Sukru Palanduz; Sukru Ozturk; Noboru Yamanaka; Kenji Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.